These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 20849311)
21. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Kwekkeboom DJ; Krenning EP; Lebtahi R; Komminoth P; Kos-Kudła B; de Herder WW; Plöckinger U; ; Neuroendocrinology; 2009; 90(2):220-6. PubMed ID: 19713714 [TBL] [Abstract][Full Text] [Related]
22. Something more than estimating renal dosimetry. Bodei L; Cremonesi M; Paganelli G Cancer Biother Radiopharm; 2010 Dec; 25(6):767-8. PubMed ID: 21204774 [No Abstract] [Full Text] [Related]
23. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115 [TBL] [Abstract][Full Text] [Related]
24. Receptor radionuclide therapy of tumors: a road from basic research to clinical applications. Bodei L; Paganelli G; Mariani G J Nucl Med; 2006 Mar; 47(3):375-7. PubMed ID: 16513604 [No Abstract] [Full Text] [Related]
25. 90Y-DOTATOC and nephrotoxicity. Otte A; Cybulla M; Weiner SM Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1543. PubMed ID: 12537003 [No Abstract] [Full Text] [Related]
26. Proceedings of the 1st International Symposium on Radionuclide Therapy and Radiopharmaceutical Dosimetry. September 4-8, 2004, Helsinki, Finland. Cancer Biother Radiopharm; 2005 Feb; 20(1):41-118. PubMed ID: 15778578 [No Abstract] [Full Text] [Related]
28. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. Vegt E; de Jong M; Wetzels JF; Masereeuw R; Melis M; Oyen WJ; Gotthardt M; Boerman OC J Nucl Med; 2010 Jul; 51(7):1049-58. PubMed ID: 20554737 [TBL] [Abstract][Full Text] [Related]
29. Radionuclide Therapies in Molecular Imaging and Precision Medicine. Kendi AT; Moncayo VM; Nye JA; Galt JR; Halkar R; Schuster DM PET Clin; 2017 Jan; 12(1):93-103. PubMed ID: 27863570 [TBL] [Abstract][Full Text] [Related]
30. Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths. Prasad V; Bodei L; Kidd M; Modlin IM Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1825-30. PubMed ID: 24806111 [No Abstract] [Full Text] [Related]
31. From the magic bullet to an effective therapy: the peptide experience. Mansi L Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1393-8. PubMed ID: 15351914 [No Abstract] [Full Text] [Related]
35. Renal dosimetry: ready for biological equivalent dose? Response to medical internal radiation dose and European association of nuclear medicine committee letters. Siegel JA; Stabin MG; Sharkey RM Cancer Biother Radiopharm; 2010 Dec; 25(6):763-5. PubMed ID: 21204773 [No Abstract] [Full Text] [Related]
36. Radiotargeting agents for cancer therapy. Kassis AI Expert Opin Drug Deliv; 2005 Nov; 2(6):981-91. PubMed ID: 16296803 [TBL] [Abstract][Full Text] [Related]
39. A theoretical radiobiological assessment of the influence of radionuclide half-life on tumor response in targeted radiotherapy when a constant kidney toxicity is maintained. Abou-Jaoudé W; Dale R Cancer Biother Radiopharm; 2004 Jun; 19(3):308-21. PubMed ID: 15285877 [TBL] [Abstract][Full Text] [Related]
40. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET. Pach D; Sowa-Staszczak A; Kunikowska J; Królicki L; Trofimiuk M; Stefańska A; Tomaszuk M; Głowa B; Mikołajczak R; Pawlak D; Jabrocka-Hybel A; Hubalewska-Dydejczyk AB Radiother Oncol; 2012 Jan; 102(1):45-50. PubMed ID: 21885142 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]